Oxurion will move the testing of THR-149 0.13 mg into part B of its phase 2 KALAHARI study, which will evaluate the drug compared with aflibercept in patients with diabetic macular edema, according to a company press release.
THR-149, a plasma kallikrein inhibitor delivered intravitreally, has shown positive results at all three dose levels administered in part A of the study to evaluate its safety and efficacy in the treatment of DME. Results demonstrated a favorable safety profile for 0.005 mg, 0.022 mg and 0.13 mg doses of THR-149 with no serious adverse events observed in any group. A mean